The subsequent dramatic and durable response to alectinib confirms this hypothesis and is consistent with the high efficacy of alectinib in ALK‐rearranged NSCLC, including its superior CNS activity [4, 5, 7]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.